In The Media
From The media
OCON Therapeutics has reached its recruitment goal of its Phase IIb clinical study evaluating the revolutionary IUB™ SEAD®, a non-invasive treatment for heavy menstrual bleeding affecting 1 in 3 women
March 24, 2023
|
Femtechworld
OCON Therapeutics is honored to be part of Bolt PR’s (A Millwright Agency) important list of Femtech Brands and Innovations to watch in 2023
March 15, 2023
|
Boltpr
OCON Therapeutics participating in the World Economic Forum’s Industry Strategy Meeting in Geneva as Technology Pioneer
March 14, 2023
|
Weforum
OCON Therapeutics’s CEO, Keren Leshem, recognized as 1 in 10 Israeli women to watch in 2023
March 10, 2023
